Multi-centre phase II trial of Thalidomide in the treatment of unresectable hepatocellular carcinoma

Acta Oncologica

Volumn 46, Issue 2, 2007, Pages 234-238

  Chuah, Benjamin ^a   Lim, Robert ^a   Boyer, Michael ^b   Ong, Ai Bee ^a   Wong, Seng Weng ^a   Kong, Hwai Loong ^a   Millward, Michael ^b   Clarke, Stephen ^b   Goh, Boon Cher ^a  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

THALIDOMIDE;

ACUTE KIDNEY FAILURE; ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSTIPATION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; EDEMA; FATIGUE; FEMALE; HEART FAILURE; HISTOLOGY; HUMAN; HUMAN TISSUE; HYPERTENSION; LETHARGY; LIVER CELL CARCINOMA; MALE; MONOTHERAPY; MULTICENTER STUDY; NEUROPATHY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RADIOLOGY; RASH; SOMNOLENCE; SUBARACHNOID HEMORRHAGE; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER NEOPLASMS; MALE; MIDDLE AGED; THALIDOMIDE; TREATMENT OUTCOME;

EID: 33847056761     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860600702076     Document Type: Article

References (25)

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001;2:533-43.
2. Schafer DF, Sorrell MF. Hepatocellular carcinoma. Lancet 1999;353:1253-7.
3. Seow WK, Chia KS, Shi LM, Lee HP, Shanmugaratnam K. Trends in cancer incidence in Singapore 1968-2002. Singapore Cancer Registry 2004; Report No. 6.
4. Ikeda K, Saitoh S, Tsubota A, Arase Y, Chayama K, Kumada H, et al. Risk factors for tumor recurrence and prognosis after curative resection of hepatocellular carcinoma. Cancer 1993;71:19-25.
5. Levin B, Amos C. Therapy of unresectable hepatocellular carcinoma. N Engl J Med 1995;332:1294-6.
6. CLIP Group (Cancer of the Liver Italian Programme). Tamoxifen in treatment of hepatocellular carcinoma: A randomised controlled trial. Lancet 1998;352:17-20.
7. Perrone F, Gallo C, Daniele B, Gaeta GB, Izzo F, Capuano G, et al. Tamoxifen in the treatment of hepatocellular carcinoma: 5-year results of the CLIP-1 multicentre randomised controlled trial. Curr Pharm Des 2002;8:1013-9.
8. Lai CL, Lau JY,Wu PC, Ngan H, Chung HT, Mitchell SJ, et al. Recombinant interferon-alpha in inoperable hepatocellular carcinoma: A randomized controlled trial. Hepatology 1993;17:389-94.
9. Venook AP. Hepatocellular carcinoma. Curr Treat Options Oncol 2000;1:407-15.
10. Hsu PI, Chow NH, Lai KH, Yang HB, Chan SH, Lin XZ, et al. Implications of serum basic fibroblast growth factor levels in chronic liver diseases and hepatocellular carcinoma. Anticancer Res 1997;17:2803-9.
11. Yoshida T, Kaneko Y, Tsukamoto A, Han K, Ichinose M, Kimura S. Suppression of hepatoma growth and angiogenesis by a fumagillin derivative TNP470: Possible involvement of nitric oxide synthase. Cancer Res 1998;58:3751-6.
12. Zhang ZL, Liu ZS, Sun Q. Effects of thalidomide on angiogenesis and tumor growth and metastasis of human hepatocellular carcinoma in nude mice. World J Gastroenterol 2005;11:216-20.
13. Kumar S, Witzig TE, Rajkumar SV. Thalidomide as an anticancer agent. J Cell Mol Med 2002;6:160-74.
14. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91:4082-5.
15. Hsu C, Chen CN, Chen LT, Wu CY, Yang PM, Lai MY, et al. Low-dose thalidomide treatment for advanced hepatocellular carcinoma. Oncology 2003;65:242-9.
16. Wang TE, Kao CR, Lin SC, Chang WH, Chu CH, Lin J, et al. Salvage therapy for hepatocellular carcinoma with thalidomide. World J Gastroenterol 2004;10:649-53.
17. Lin AY, Brophy N, Fisher GA, So S, Biggs C, Yock TI, et al. Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma. Cancer 2005;103:119-25.
18. Patt YZ, Hassan MM, Lozano RD, Nooka AK, Schnirer, II, Zeldis JB, et al. Thalidomide in the treatment of patients with hepatocellular carcinoma: A phase II trial. Cancer 2005;103:749-55.
19. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
20. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1-10.
21. Giantonio BJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. Prog Proc Am Soc Clin Oncol 2005;2, abstract.
22. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
23. Lin MI, Sessa WC. Antiangiogenic therapy: Creating a unique "window" of opportunity. Cancer Cell 2004;6:529-31.
24. Ng SS, Figg WD. Upregulation of endogenous angiogenesis inhibitors: A mechanism of action of metronomic chemotherapy. Cancer Biol Ther 2004;3:1212-3.
25. Patt YZ, Hassan MM, Lozano RD, Ellis LM, Peterson JA, Waugh KA. Durable clinical response of refractory hepatocellular carcinoma to orally administered thalidomide. Am J Clin Oncol 2000;23:319-21.